Novel Type 1 and Type 3 Live Attenuated Oral Poliovirus Vaccines Show Comparable Safety, Immunogenicity, and Shedding to Sabin mOPV in First‑in‑Human Phase 1 Trial
Posted inInfectious Diseases news Public Health

Novel Type 1 and Type 3 Live Attenuated Oral Poliovirus Vaccines Show Comparable Safety, Immunogenicity, and Shedding to Sabin mOPV in First‑in‑Human Phase 1 Trial

A multicentre phase 1 trial in healthy US adults found nOPV1 and nOPV3 were well tolerated and induced robust homotypic neutralising antibody responses with shedding profiles similar to Sabin monovalent OPV, supporting progression to phase 2 studies.
Both Too Little and Too Much Respiratory Drive and Effort Predict Worse Outcomes on Mechanical Ventilation: Insights from a Prospective Toronto Cohort
Posted inCritical Care news Respiratory

Both Too Little and Too Much Respiratory Drive and Effort Predict Worse Outcomes on Mechanical Ventilation: Insights from a Prospective Toronto Cohort

A prospective registry study found a U-shaped relationship between respiratory drive/effort and ICU outcomes: both low and high drive/effort linked with higher mortality and slower discharge, especially when oxygenation (PaO2:FiO2) ≤150 mmHg; ventilator driving pressure effects were amplified by patient effort.
Checkpoint inhibition for frail patients: Durvalumab with carboplatin–etoposide shows tolerability and a 1‑year survival signal in poor‑performance‑status extensive‑stage SCLC (NEJ045A)
Posted innews Oncology Respiratory

Checkpoint inhibition for frail patients: Durvalumab with carboplatin–etoposide shows tolerability and a 1‑year survival signal in poor‑performance‑status extensive‑stage SCLC (NEJ045A)

NEJ045A shows durvalumab plus carboplatin–etoposide is feasible in ES‑SCLC patients with PS2–3, with induction completion rates above thresholds and a 1‑year survival of 43.4% overall, supporting cautious use of chemo‑immunotherapy in selected frail patients.
Dupilumab Surpasses Omalizumab for Type‑2 Respiratory Disease: Converging Evidence from a Head‑to‑Head RCT, Real‑World US Data, and a Target‑Trial Emulation
Posted inAllergy & Immunology news Respiratory

Dupilumab Surpasses Omalizumab for Type‑2 Respiratory Disease: Converging Evidence from a Head‑to‑Head RCT, Real‑World US Data, and a Target‑Trial Emulation

Three complementary studies—EVEREST (head‑to‑head RCT), the US ADVANTAGE real‑world study, and a target‑trial emulation—consistently show greater reductions in nasal polyp burden, smell loss, asthma exacerbations, and systemic steroid use with dupilumab versus omalizumab in type‑2 respiratory disease.
Large Phase 3 Trials Show No Cognitive Benefit with Iclepertin in Schizophrenia — What the CONNEX Programme Teaches Us About Treating CIAS
Posted innews Psychiatry

Large Phase 3 Trials Show No Cognitive Benefit with Iclepertin in Schizophrenia — What the CONNEX Programme Teaches Us About Treating CIAS

Three multinational phase 3 trials found no clinically meaningful cognitive benefit of the GlyT1 inhibitor iclepertin versus placebo in schizophrenia, though the drug was well tolerated. Results highlight methodological and biological challenges in developing treatments for cognitive impairment associated with schizophrenia.
Normalising Renin After Medical Therapy for Primary Aldosteronism May Lower Cardiovascular Risk — But RCTs Are Needed
Posted inCardiology Diabetes & Endocrinology news

Normalising Renin After Medical Therapy for Primary Aldosteronism May Lower Cardiovascular Risk — But RCTs Are Needed

A 2025 systematic review and meta-analysis found that patients with primary aldosteronism whose renin rose after mineralocorticoid receptor antagonist therapy had substantially lower cardiovascular event rates and possibly lower mortality, suggesting renin normalisation as a therapeutic target pending prospective confirmation.
Cyclic Cushing’s Syndrome: International Cohort Reveals Diagnostic Pitfalls, High Complication Rates, and Practical Strategies for Clinicians
Posted inDiabetes & Endocrinology news

Cyclic Cushing’s Syndrome: International Cohort Reveals Diagnostic Pitfalls, High Complication Rates, and Practical Strategies for Clinicians

An international retrospective cohort of 110 patients with cyclic Cushing’s syndrome highlights frequent diagnostic delays, imaging misses, inappropriate surgeries, high rates of spontaneous adrenal insufficiency, and variable outcomes — prompting practical recommendations for testing, sampling timing, and peri‑care planning.
Tailored Implementation of Systems Navigation and Psychosocial Counselling to Enhance HIV Care Engagement among People Who Inject Drugs in Viet Nam: Evidence from a Cluster-Randomised Trial
Posted inClinical Updates HIV/AIDS news

Tailored Implementation of Systems Navigation and Psychosocial Counselling to Enhance HIV Care Engagement among People Who Inject Drugs in Viet Nam: Evidence from a Cluster-Randomised Trial

A tailored approach to implementing systems navigation and psychosocial counselling significantly improved intervention fidelity and viral suppression among people with HIV who inject drugs in Viet Nam, compared to a standard strategy, highlighting the value of context-sensitive interventions.
Mirikizumab Shows Promising Efficacy and Acceptable Safety in Pediatric Moderately-to-Severely Active Ulcerative Colitis: Results from the SHINE-1 Phase 2 Trial
Posted inGastroenterology news Pediatrics

Mirikizumab Shows Promising Efficacy and Acceptable Safety in Pediatric Moderately-to-Severely Active Ulcerative Colitis: Results from the SHINE-1 Phase 2 Trial

The multicentre open-label SHINE-1 phase 2 trial found that mirikizumab produced clinically meaningful induction and maintenance responses in children with moderate-to-severe ulcerative colitis, with an acceptable safety profile over 52 weeks, supporting further randomized evaluation.